Trial | NCT02539706  Report issue

Title

Menstrual Cycle on Injection Pain of Rocuronium
The Impact of the Menstrual Cycle on Injection Pain of Rocuronium

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    rocuronium ...

  • Study Participants

    100
This study evaluates the effects of rocuronium injection pain to menstrual cycle phases.Half of participants will receive follicular phase, while the other half will receive luteal phase.
Menstrual period includes a spectrum of emotional and somatic symptoms observed in luteal phase of menstrual cycle, which are disappeared after menstruation.

During menstrual cycle, fluctuation in sexual hormones results in attitude change and alteration in pain perception.

Different studies reported some interactions between sex hormones and central nervous system, which might be linked to activity of serotonin and beta-endorphin in the brain.

Pain perception differs during menstrual cycle.

It has been recommended that estrogens might have an influence on somatic sensory process.

Some studies reported a significant effect of pain sensitivity with higher levels of progesterone and some other studies reported similar patterns for pain perception.

There are reports of more complaint of pain in luteal phase of menstruation, which is suggested as the reason for functional changes in women during menstrual cycle.
Study Started
Jan 06
2014
Primary Completion
Sep 06
2015
Study Completion
Oct 06
2015
Last Update
Nov 29
2017

Drug Rocuronium 0,6mg/kg

patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous was applied

  • Other names: esmeron

Drug Rocuronium 0,6mg/kg

patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied

  • Other names: esmeron

Follıcular group Experimental

patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.

Luteal group Active Comparator

patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.

Criteria 

Inclusion Criteria:

American Society of Anesthesiology Classification (ASA) I-II
18-45 years
Regular menstrual cycle

Exclusion Criteria:

Irregular menstrual cycles
Patients receiving hormones or drugs affecting the ovulatory cycle
Amenorrhea
Pregnancy
Climacteric patients
No Results Posted